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Abstract
Background The UK’s transition from the European Union creates both an urgent need and key opportunity for the UK 
and its global collaborators to consider new approaches to the regulation of emerging technologies, underpinned by regula-
tory science. This survey aimed to identify the most accurate definition of regulatory science, to define strategic areas of 
the regulation of healthcare innovation which can be informed through regulatory science and to explore the training and 
infrastructure needed to advance UK and international regulatory science.
Methods A survey was distributed to UK healthcare professionals, academics, patients, health technology assessment agen-
cies, ethicists and trade associations, as well as international regulators, pharmaceutical companies and small or medium 
enterprises which have expertise in regulatory science and in developing or applying regulation in healthcare. Subsequently, 
a descriptive quantitative analyses of survey results and directed thematic analysis of free-text comments were applied.
Results Priority areas for UK regulatory science identified by 145 participants included the following: flexibility: the capa-
bility of regulations to adapt to novel products and target patient outcomes; co-development: collaboration across sectors, 
e.g. patients, manufacturers, regulators, and educators working together to develop appropriate training for novel product 
deployment; responsiveness: the preparation of frameworks which enable timely innovation required by emerging events; 
speed: the rate at which new products can reach the market; reimbursement: developing effective tools to track and evaluate 
outcomes for “pay for performance” products; and education and professional development.
Conclusions The UK has a time-critical opportunity to establish its national and international strategy for regulatory science 
leadership by harnessing broader academic input, developing strategic cross-sector collaborations, incorporating patients’ 
experiences and perspectives, and investing in a skilled workforce.
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Introduction
The UK’s capability to adapt its regulatory frameworks 
in healthcare is under pressure. The pace of emerging 
technologies and the COVID-19 pandemic makes this a 
global issue. Furthermore, the UK leaving the European 
Union (EU) adds a significant, specific national need 
for change, carrying opportunity and risk that must be 
carefully managed. The scale and pace of innovation in 
existing and emerging technologies has outstripped the 
UK’s longstanding regulatory frameworks, and economic 
incentives need to be carefully counterbalanced by a key 
focus on patient safety, as well as evolving standards of 
evidence of efficacy. Regulatory science will be crucial to 
this endeavour.
Regulatory science in healthcare can be broadly defined 
as “the application of the biological, medical and sociolog-
ical sciences to enhance the development and regulation 
of medicines and devices in order to meet the appropriate 
standards of quality, safety, and efficacy” [1]. However, 
there is no consensus definition, as different organisations 
such as US Food and Drug Administration (FDA) [2], the 
European Medicines Agency (EMA) [3] and the Pharma-
ceutical Society of Japan (PSJ) [4] have proposed their 
own definitions.
Regulatory frameworks face several parallel devel-
opments which undermine their effectiveness. Firstly, 
medical technologies, clinical practice and societal/pub-
lic needs are rapidly evolving in fields such as digital 
devices, personalised medicine, health data and artificial 
intelligence (AI), as well as novel trial design and patient 
centricity in drug development [5–7]. These come with 
vast opportunities but also some significant risks to users, 
innovators, and payers [8]. However, through the develop-
ment of regulatory and scientific strategy, planning and 
governance regulatory science can be future-proofed [9]. 
Secondly, post-Brexit, the UK intends to separate from EU 
regulations at the end of the transition period, 31 Decem-
ber 2020. Currently, the UK Government is planning to 
develop a regulatory framework for medicines and medical 
devices that will allow the fast approval of the most inno-
vative and cost-effective products for the National Health 
Service (NHS) while maintaining a globally competitive 
and internationally collaborative position [10, 11]. Finally, 
the tremendous national and international efforts to tackle 
COVID-19 have highlighted both challenges and benefits 
of regulatory flexibility in rapid but effective support for 
new diagnostics and vaccines in response to the pandemic.
The importance and the scope of regulatory science 
may not always be fully recognised by academic, policy 
and clinical communities, whose focus may be either tech-
nological innovation or producing evidence on the safety, 
effectiveness and cost-effectiveness of interventions to 
inform regulators and policymakers, rather than the sci-
ence of developing new tools, standards and approaches 
to underpin advances in regulation [12]. Hence, opportu-
nities for successful collaboration can be missed between 
academic, clinical, pharmaceutical, health technology and 
regulatory scientists, as well with patients and the public 
themselves, whose ‘voice’ is essential in the development 
of healthcare interventions. Such lost opportunities may 
come with societal costs of delayed licensing—and thus 
delayed patient benefit—or conversely, underestimated 
risks of adverse effects of already licenced products and 
technologies.
To meet the challenges outlined above, a well-informed 
and well-coordinated UK environment for regulatory change 
in healthcare, underpinned by strong regulatory science, is 
required, which must leverage collaboration with academia, 
industry, patients, regulators and international stakeholders. 
This manuscript aimed to identify the most accurate defini-
tion of regulatory science, identify critical emerging chal-
lenges and opportunities in regulatory science, define stra-
tegic areas of regulation of healthcare innovation which can 
be enabled through regulatory science and explore training 
and infrastructure needed to advance UK and international 
regulatory science. The authors represent a consortium of 
stakeholders keen to raise the profile of regulatory science in 
the UK; the article aims to promote debate and drive action.
Methods
An anonymised online survey (Appendix 1) was developed, 
containing questions on (1) demographics, (2) the definition 
of regulatory science in healthcare, (3) current challenges 
and opportunities for UK regulatory science, (4) strategic 
areas for development, (5) current training and future needs, 
and (6) infrastructure required. The ‘Current challenges and 
opportunities’ section was based upon ‘The Development 
of Regulatory Science in the UK: A Scoping Study’ [1] 
and the European Medicines Agency’s goals for regulatory 
science to 2025 [6]. Four of the main “Strategic areas for 
development” were extracted verbatim from the Medicines 
and Healthcare Products Regulatory Agency (MHRA) Cor-
porate Plan 2018–2023 [12]. The MHRA Corporate Plan 
includes the strategic area “Public health and partnership” 
which was replaced in the survey with “Patient-centred drug 
development” to emphasise the crucial role of patients in the 
development of healthcare products.
The section “Current training and future needs” aimed 
to explore awareness and availability of the training, both 
within and outside of UK, barriers and enablers for the 
existing offer, and future training needs. Additionally, 
views on the focus and the level of education and training 
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were sought. The questions on the existing and desira-
ble collaborations and infrastructure were to identify the 
needs and to inform the role of academia within regulatory 
science.
Questions contained space for free-text comments, to 
allow respondents to expand on their answers or challenge 
the authors’ assumptions. The team decided to remove the 
free-text comments to avoid compromising the identity 
of some of the participants. The survey was pilot-tested 
among three regulatory science experts. No changes to the 
survey questions were required; however, some amend-
ments were made to the front page of the survey and par-
ticipant information sheet. The changes helped to clarify 
that all participants’ answers would be anonymous and 
their answers would not be identified. This study was 
approved by the ethical review committee at the University 
of Birmingham, UK (ERN_20-0268).
The participant information sheet [(Appendix 2) Elec-
tronic supplementary material] was provided to potential 
participants electronically prior to the survey comple-
tion. Survey participants were asked to give consent on 
the first page of the study; if consent was not given, they 
were not able to progress to the next part of the survey. 
The survey targeted national healthcare professionals, 
academics, patient advocates, health technology assess-
ment agencies, ethicists and trade associations and interna-
tional regulators, pharmaceutical companies and small or 
medium enterprises involved in regulatory science, either 
developing or applying regulation in a healthcare setting. 
Respondents were volunteers from a sample of eligible 
individuals recruited through stakeholder organisations 
and collaborators with relevant experience in regulatory 
science. Furthermore, stakeholders contacted were asked 
to refer further potential participants (snow-ball recruit-
ment). Data were collected between April and May 2020. 
The survey was hosted by SmartSurvey™.
Analysis
Descriptive quantitative analysis was undertaken for each 
respondent group. Frequency distributions were used to 
describe respondent characteristics and survey responses. 
SCR undertook direct content analysis of the free-text com-
ments responses [13]. Survey data were managed using a 
qualitative data analysis software package (QSR NVivo 
12). The analysis process started with reading the survey 
responses several times to increase familiarity with the data. 
This was followed by inductive coding process. The coding 
was reviewed by BT and any disagreements about the cod-
ing were discussed and resolved with a third reviewer (MJC, 
EM and AKD).
Results
A total of 145 participants took part in the survey, and 
all responses were anonymised. Ninety-one percent 
(132/145) of the respondents were UK stakeholders while 
7% (13/145) were international, mainly from the United 
States and Europe. Thirty-two questionnaires were par-
tially completed. These were only included in the data 
analysis if they had responses completed to at least one 
of the key “Strategic areas for development” questions, as 
they provided essential information on the criteria areas 
for the development of UK regulatory science.
Table 1 outlines the characteristics of the participants. 
Stakeholders’ background included a wide range of clini-
cal and methodological expertise, including pharmacovigi-
lance and regulatory affairs. See Appendix 3 (Electronic 
supplementary material) for further details.
Defining Regulatory Science in Healthcare
As noted, several international agencies such as the EMA 
and FDA and international networking groups like the Col-
laboration for the Advancement of Sustainable Medical 
Innovation (CASMI) and the PSJ have proposed different 
definitions of healthcare regulatory science. Stakeholders 
were asked to select the most accurate definition based on 
their understating of the discipline.
The most agreed definition among participants (50%) 
was the one provided by the EMA: “Regulatory Science 
can be described as a range of scientific disciplines that 
are applied to the quality, safety and efficacy assessment of 
medicinal products that inform regulatory decision-mak-
ing throughout the lifecycle of a medicine. It encompasses 
basic and applied medicinal science and social sciences 
and contributes to the development of regulatory standards 
and tools” [14]. The next most supported was the CASMI 
definition (18%): “The application of the biological, medi-
cal, and sociological sciences to enhance the development 
and regulation of medicines and devices in order to meet 
the appropriate standards of quality, safety and efficacy” 
[1].
However, one participant (1%) commented that the most 
accurate definition of regulatory science should be a com-
bination of the FDA and EMA definitions. One participant 
proposed combining the FDA and CASMI definitions, and 
another participant proposed combining the CASMI and 
PSJ ones. Two participants suggested modifying the EMA 
definition by adding the term ‘medical devices’ and one 
suggested substituting the term ‘throughout the life cycle’ 
for ‘any regulated product, service or system’. One par-
ticipant suggested revising the FDA definition to broaden 
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the term ‘FDA-regulated products’ to ‘medicines, devices 
and other health technologies’. One participant suggested 
adding the wording ‘that patients expect and deserve’ at 
the end of the CASMI definition. Lastly, three participants 
suggested their own definitions of regulatory science in 
healthcare.
Areas of UK Healthcare Regulation that can be 
Enabled Through Regulation
Participants ranked the top six outcomes of future regula-
tion which regulatory science needs to effectively enable 
(Table 2).
Participants highlighted several challenges and oppor-
tunities that need to be addressed to drive the outcomes 
proposed in Table 2. The most common were as follows: 
cooperation between agencies (e.g. MHRA, EMA and FDA) 
82% (119/145); dialogue/cooperation across stakeholders 
(e.g. academia, regulatory agencies and patients/patient 
advocates) 76% (110); development of a framework to make 
regulatory decisions about risks and benefits of products that 
increasingly involve new technology (e.g. digitally based 
products/AI and product development, production processes 
and novel supply chains) and target patient outcomes 70% 
(102); data sharing 63% (92); and technological and scien-
tific challenges—genomics and increased personalisation/
specialisation of products 50% (73). See Appendix 4 for 
further challenges and opportunities.
Strategic Areas for Development
Table 3 presents the top three priorities that participants 
considered the most important for the development of UK 
regulatory science according to the following strategic areas 
identified in the MHRA corporate plan: (a) patient-centred 
drug development; (b) enhancing innovation; (c) proactive, 
Table 1.  Participants’ characteristics.
* Other: regulatory consultancy, government body, clinical research organisation/practitioner, service provider to the pharma industry.
Stakeholder group n (%), N = 145
Pharmaceutical company and large med-tech 31 (21)
Academic 26 (18)
Regulator 17 (12)
Healthcare professional 14 (10)
Patient representative 14 (9)
Small- or medium-size enterprise 9 (6)
Health Technology Assessment agency 5 (3)
Ethicists 3 (2)
Trade association 2 (1)
Other* 26 (18)
Years of experience in regulatory science n (%)
Less than 1 year of experience 9 (6)
2 – 5 years 37 (25)
6 – 10 years 18 (12)
More than 10 years 81 (56)
Table 2.  Six most important outcomes of UK regulation and innovation which regulatory science needs to effectively enable.
Strategic outcomes
1 Flexibility: the capability of regulations to adapt to novel products and target patient outcomes
2 Co-development: collaboration across sectors, e.g. patients, manufacturers, regulators and educators working 
together to develop appropriate training for novel product deployment
3 Responsiveness: the preparation of frameworks which enable timely innovation required by emerging events
4 Speed: the rate at which new products can reach the market
5 Reimbursement: developing effective tools to track and evaluate outcomes for “pay for performance” products
6 Education and professional development
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robust surveillance; and (d) organisational excellence/
efficiency.
Existing Cross‑Sector Training and Workforce 
Development Needs
The participants reported the need for life-long learning to 
keep pace with the breath and dynamism of regulatory sci-
ence. This learning and development should be responsive 
to the constant advancement of innovative technologies 
and products. Fifty-five percent (68/124) of respondents 
were unaware of any training courses or training schemes 
in regulatory science. Training opportunities in UK (45%, 
56/124), in the United States (26%, 32/124), and in other 
European countries (19%, 24/124) were marked as most 
commonly known to the responders. The most frequently 
attended courses by the respondents were these delivered 
by The Organisation for Professionals in Regulatory Affairs 
(TOPRA), the MHRA, FDA, EMA, Pharmaceutical Infor-
mation and Pharmacovigilance Association (PIPA), Drug 
Information Association (DIA) and King’s College Lon-
don University. Please see Appendix 4 (Electronic supple-
mentary material) to see other courses mentioned by the 
participants.
The survey results showed that 67% (83/124) of partici-
pants had not attended training courses. The reasons listed 
included the following: (a) lack of awareness of the courses, 
(b) lack of funding for attendance, (c) courses not meeting 
the stakeholders’ needs or not being relevant to them, (d) 
time constraints and (e) courses not being freely available 
for patients/patient advocates. Participants confirmed that 
training is essential to meet the current (79%, 94/119) and 
future (85%, 94/119) needs of regulation. They suggested 
that regulatory science education and training should be 
delivered at continuing professional development (CPD) 
courses (87%, 104/119), postgraduate taught Master of Sci-
ence (MSc) degree (62%, 74/119), postgraduate research 
Master of Research (MRes) or PhD degree (52%, 62/119), 
cross-sector fellowships (48%, 57/119) and academic fellow-
ships (45%, 53/119).
Stakeholders expressed that additional training formats 
such as online training, short intensive courses, short courses 
at conferences and big meetings, training for patients/patient 
advocates and free webinars would be beneficial to advance 
regulatory science. The following topics were proposed: 
biologics and advanced therapies, ethics and governance, 
new medical device regulations, omics and its use in clinical 
and regulatory science and understanding AI and machine-
learning processes.
Table 3.  Top three priorities per strategic areas of development.
Patient-centred drug development n (%), N = 135
Ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug 
development and evaluation
104 (77%)
Enhance understanding and appropriate use of methods to capture information on patient preferences and the potential accept-
ability of trade-offs between treatment benefit and risk outcomes
84 (62%)
Reinforce patient relevance in evidence generation, increased patient involvement in regulatory activities, including patient 
representatives as additional experts in Scientific Advisory Groups, as well as patient contribution to scientific advice and 
protocol assistance
81 (60%)
Enhancing innovation n (%), N = 131
Explore innovative ways of using real-world data to assess clinical effectiveness in routine clinical settings 86 (66%)
Explore developing standards for new areas, e.g. digital health, artificial intelligence, including machine learning 84 (64%)
Explore developing more agile regulatory approvals processes for novel and generic products 79 (60%)
Proactive and robust surveillance n (%), N = 125
Optimise signal and risk assessment functions to respond to risks in real time 75 (60%)
Enhance information sharing 70 (56%)
Develop systems and processes for integrated medicines and devices surveillance 68 (54%)
Organisational excellence/efficiency n (%), N = 124
Explore opportunities to develop collaborations and information sharing with key global regulators, international partnerships 
with WHO (World Health Organisation) and other key players
92 (74%)
Invest in scientific capabilities to meet emerging needs. Invest in staff’s specialist skill sets, and in facilities to deliver state of the 
art regulation and services
87 (70%)
Identify future capability needs and ensure the right skill mix is available to support innovation and deliver priority programmes 
and core functions
83 (67%)




In terms of regulatory science infrastructure, the majority of 
participants (85%, 101/119) expressed that they know how 
to access expertise when working in a highly regulated area. 
Additionally, 76% (91/119) of the participants had knowl-
edge of the MHRA Innovation Office although only 24% 
(28/119) had accessed this support.
Successful Cross‑Sector Collaborations and Barriers 
in Creating Collaborations
Survey respondents provided several examples of national 
and international collaborations for the development of 
health products across disciplines. These included but were 
not limited to: (i) international joint efforts to tackle COVID-
19 by developing vaccines, ventilators and conducting fur-
ther relevant research, (ii) development of a machine-learn-
ing algorithm for eye disease diagnosis, (iii) AI for breast 
cancer screening and (iv) predicting patients at risk of sud-
den cardiac death after myocardial infarctions. Table 4 pre-
sents different elements that made these and other collabo-
rations successful and examples of challenges that survey 
responders have encountered such as legal, structural and 
ethical barriers while developing cross-sector collaborations.
Academic Leadership
The need for academic leadership in the UK in developing 
cutting-edge technologies to evaluate safety, efficacy, quality 
and performance of new health products and technologies 
was expressed by 80% of the responders (92/115). Accord-
ing to survey respondents, the main areas that would ben-
efit from academic leadership, currently and in future, are 
innovative trial design (68%, 78/114—mainly supported by 
academics (57%, 15/26) and regulators (88%, 15/17)), real-
world evidence (67%, 76/114—mainly supported by aca-
demics (57%, 15/26)), patient-centred technology develop-
ment (64%, 73/114—mainly supported by academics (46%, 
12/26), healthcare professionals (85%, 12/14) and patient 
representatives (85%, 12/14), and AI in healthcare (62%, 
71/114—mainly supported by academics (65%, 17/26 and 
regulators (64%, 11/17)). Furthermore, participants pro-
posed additional areas such as data ethics, advanced ther-
apy medicinal products, genomics and regulation of clinical 
trials.
In addition, some participants suggested that academia 
can play a leadership role in new methods development, 
Table 4.  Key considerations and barriers in collaboration on health products development.
Considerations Barriers
● Strong and cross-sector collaborations (e.g. academia, patient-repre-
sentative bodies/charities, regulators and industry)
● Early engagement and communication with stakeholders
● Patient and public involvement
● Availability of funding
● Recruitment and availability of appropriate expertise
● Stakeholders’ aligned strategies and common purpose
● Flexibility in considering different stakeholders’ perspectives
● Transparency
● Perspectives of end users well captured and integrated into the 
research design
● Training available related to the research being conducted
● Adapting to changing regulatory environment
Legal barriers
● Intellectual property (IP) concerns and ownership
● Data sharing, access agreements and confidentiality
● Difficulty agreeing terms for contracts between academia and industry 
(e.g. data sharing)
Structural barriers
● Differences between regulatory requirements between Europe, the UK 
and US
● Differences in regulatory requirements for CT products and medical 
devices
● Uncertain regulatory guidance around AI and ML algorithms
● Multiple levels of clearance/review in regulatory agencies
● Lack of capacity from MHRA regulatory, specifically in the medical 
devices area
● Conservatism or ‘old school’ thought process prevalent among com-
panies and agencies
● Insufficient funding to support a full research project
Other barriers
● Lack of information sharing between MHRA and NICE
● Lack of trust between health systems (e.g. NHS) and pharmaceuticals
● Language barriers encountered in contracts which delays the research 
process
● Potential conflict of interest as an impediment/prevention from 
collaboration taking place (e.g. inability of third-party independent 
organisations to accept money from industry)
● Excessive time needed to reach collaborative agreement
● Excessive workload as barrier to CPD and career development
● Cultural differences
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particularly around the regulation and ongoing evaluation 
of new technologies where the existing regulatory frame-
work is insufficient, such as AI and digital health technolo-
gies. Survey participants reinforced a need for academia 
to provide regulatory courses for workforce development, 
particularly to benefit clinicians, industry and regulators. 
Eight participants noted the need for academic leadership in 
collaboration with industry, health professionals, regulators 
and patient advocates to develop effective and appropriate 
regulation of innovative healthcare products.
Discussion
This survey aimed to assess stakeholder views on the defi-
nition of regulatory science and explore critical challenges 
and opportunities in regulatory science for UK healthcare. 
Several key messages emerged. Firstly, there was a lack of 
agreement upon the existing and proposed definitions of reg-
ulatory science in healthcare although a significant buy-in to 
the existing EU-level definition was seen. The current defi-
nitions address specific stakeholder needs, for example the 
EMA definition is focussed, unsurprisingly, on medicines, 
whilst the patient perspective is not often mentioned. Thus, 
there is a need for further discussion to seek agreement on 
the most appropriate definition of regulatory science in 
healthcare in the UK in order to underpin a coherent future 
strategy, incorporating views from a range of stakeholders. 
In addition, it is necessary to discuss the different subdisci-
plines embraced within the definition of regulatory science, 
proposed by the EMA and CASMI, referring to medical, 
biological and sociological sciences.
The most important feature of future UK regulation iden-
tified by survey participants was flexibility (Table 2)—the 
capability of regulations to adapt to novel products and tar-
get patient outcomes facilitated through cooperation between 
relevant agencies, which is essential to enable some element 
of regulatory science future-proofing [9]. This mirrors 
international trends supporting increased globalised devel-
opment of health products through collaborative working 
across international regulatory agencies. Since 2003, when 
a memorandum of understanding and confidentiality agree-
ment was signed between the FDA and EMA, these two and 
subsequently other regulatory agencies have been meeting 
to discuss experiences and developments of regulatory sci-
ence [15]. Over the years, formal clusters of such informa-
tion exchange, many underpinned by legal agreements, have 
been created to cover many therapeutic areas or types of 
products. The regulatory authorities remain in close, nearly 
daily, dialogue [15]. Up until the UK’s departure from the 
EU, the MHRA has been part of these collaborations rep-
resenting the UK as part of the EMA network. It is vital 
that the UK’s participation, profile and leadership of such 
international discussions are not only preserved but further 
enhanced where possible if the UK expects to remain a glob-
ally competitive marketplace and supporter of innovation in 
healthcare.
Other important features to facilitate advances in regu-
latory science were “Broader cooperation and dialogue 
between stakeholders such as academia, industry, regula-
tory agencies and patients”, followed by “Development of a 
framework of regulatory decision-making on weighing risks 
and benefits of products involving new technologies” and 
“Data sharing”. These features again emphasise the value of 
collaborative efforts in managing both UK and global health-
care innovation, and the importance of relevant regulations 
to keep pace not only with the emerging technologies but 
also with the development of appropriate methods of their 
assessment, which is a whole new science in its own right. In 
particular, this highlights the need to create systems which 
can appropriately provide assurance of adaptive algorithms’ 
performance, which will change over time and across popu-
lations, learning from the data to which they are exposed. 
Regulation of such systems cannot simply be more of the 
same, but is likely to benefit from regulatory innovation that 
is based on a deep understanding of the technology [16].
The existing UK industry sectors have a “very real and 
concerning lack of readiness” [17] for new regulations, even 
while flexibility and innovation in future regulations have 
been prioritised in key recent strategic recommendations 
including the UK R&D Roadmap [18] and the Life Sci-
ences Recovery Roadmap supported by the UK’s industry 
trade associations [19]. The responses to the survey clearly 
highlight the importance of cross-stakeholder working to 
overcome these challenges in a timely and effective way.
Survey participants recognised the importance of 
patient-centred drug development, championed by both the 
MHRA and EMA. This recognition reinforces the consist-
ent message for greater involvement of patient advocates 
in regulatory activities and therapeutic development [20, 
21]. Increased partnership, collaboration and engagement 
of patients and the public have the potential to ensure that 
patients receive timely access to innovative products and that 
health care providers have the information needed to inform 
healthcare choices. This can be achieved by improving the 
way regulators share and communicate safety messages to 
clinicians and patients, optimising licensing pathways and 
exploring opportunities to develop more agile, transpar-
ent and joined up approval procedures [6, 20]. In addition, 
methodological issues surrounding the subject of capturing 
patients’ preferences and acceptability of trade-offs were 
raised. Improvement of methods is necessary to enhance 
the understanding of their appropriate use and interpretation. 
Together, promoting patient-centred drug development and 
enhancing methodological issues create a powerful, cross-
stakeholder call to action for the UK to develop effective 
 Therapeutic Innovation & Regulatory Science
1 3
mechanisms for working closely with patients and the public 
to build public trust, robust discussion and input, and shared 
understanding of the importance of effective regulation.
In the area of enhancing innovation, the need for explor-
ing ways of using real-world data to assess clinical effec-
tiveness in routine clinical setting was valued most highly 
by survey participants, according to the MHRA corporate 
plan’s strategic areas of development. Other prioritised 
actions were the development of standards for new tech-
nologies and the need for a more agile approval process. 
Optimising signal and risk assessment functions to respond 
to risks in real time was considered most important within 
the proactive and robust surveillance strategic area of devel-
opment. All of this speaks to the need for flexibility, effi-
ciency and an acceleration of regulation which responds to 
emerging data for novel technologies rather than relying on 
existing frameworks, regulatory or otherwise, which may 
in some instances be outdated. Further examination of the 
potential to couple implementation, evaluation and regula-
tion in the UK’s future strategy could be a highly valuable 
focus for regulatory science.
Stakeholders recognised that it is essential to develop 
collaboration and share information with key international 
regulators and partner with key players such as WHO, when 
thinking of the development of regulatory sciences in organ-
isational excellence and efficiency. In addition, they high-
lighted the need of investing in workforce skills and facilities 
to deliver novel regulatory services. This echoes previous 
points about the value of considering the UK’s future strat-
egy in a global context and particularly the development of a 
workforce capable of understanding international compara-
tors and collaborators to achieve the best outcomes. Regula-
tory experts should work in close partnership with relevant 
regulatory service providers, learning from one another to 
maximise relevance and responsiveness.
Regulatory science training is essential due to the rapid 
emergence of innovative technology and products; however, 
the survey identified that 67% of the participants have not 
attended any regulatory science training, most commonly 
due to lack of awareness of its existence. Potential rea-
sons for stakeholders not looking into training are lack of 
employer’s funding, stakeholders’ lack of time to commit to 
the course length and the courses not being relevant to the 
stakeholders’ career needs.
Stakeholders expressed that regulatory training should be 
mainly delivered through CPD courses. However, the need 
for formal education such as MSc or PhD programmes was 
also suggested. Topics covering real-world evidence, biolog-
ics and advanced therapies, AI and ethics and governance 
were especially in demand. This reflects the need for both 
regulators and innovators to understand emerging technolo-
gies—and the barriers and enablers which will allow their 
reach through to patients—through a consistent, shared 
training framework. Participants were supportive of this 
being led by academia; however, the benefits highlighted 
elsewhere of cross-sector collaboration, particularly with 
patients and the public, would certainly be critical to ensur-
ing this is as relevant and responsive as possible. A list of 
existing national and international educational programmes 
is available at the Advancing Regulatory Science and Inno-
vation in Healthcare report by Birmingham Health Partners 
[22].
For UK regulatory science to retain a competitive and 
collaborative position within the global market post-Brexit, 
participants reinforced the need for strong, cross-sector col-
laboration to develop critical infrastructure involving aca-
demia, patient-representative bodies, charities, regulators 
and industry. However, multiple barriers make such col-
laborations difficult. Among them, most commonly identi-
fied were various legal restrictions especially those around 
intellectual property, data sharing and access not only with 
international partners but even internally within the UK. In 
addition, the UK must continue to probe these stumbling 
blocks and look to adopt or create good practice which can 
be shared globally to better enable the collaborations which 
are clearly vital to future regulatory innovation.
Academic leadership in development of regulatory sci-
ence, which would allow regulators to more effectively 
keep pace with scientific development, was supported by 
the majority of participants. Importantly, academia was not 
perceived as the sole driving force but rather as a partner in 
collaboration with other stakeholders. The areas of particular 
need for academic input were innovative trial designs, real-
world evidence, patient-centred technology development and 
AI. Partnership between academia and regulators is essential 
to enable and leverage research and innovation in regulatory 
science [6]. UK universities are internationally recognised 
for their research in healthcare, law, ethics, social policy, 
health economics, engineering, business, biological sciences 
and chemistry, among other multidisciplinary programmes. 
Expertise from each of these should be contributing to regu-
latory innovation. However, only a small number of universi-
ties teach aspects of regulatory science, and none of these 
cover a fraction of the breadth of disciplines outlined above 
[22]. The UK has the potential to develop a regulatory sci-
ence fellowship programme similar to the one provided by 
the Oak Ridge Institute for Science and Education (ORISE) 
Research Participation Program at the FDA [23]. This edu-
cational and training programme aims at providing college 
students, recent graduates and university faculty opportuni-
ties to access unique research and training opportunities, 
state of the art facilities and equipment and staff in order 
to more effectively implement novel technologies within 
healthcare.
This survey presented some limitations. The sam-
pling method was not random but based on pre-selected 
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stakeholder representatives allowing for the snow-balling 
approach, which was considered more appropriate for such 
a highly technical subject. The authors acknowledge that 
their interest in this area may have influenced the framing 
and approach to the survey; please refer to the ‘competing 
interest’ section below. The survey did not assess the need 
for continued maintenance of standards in regulatory science 
for conventional evaluation methodologies for drugs and 
devices, such as various forms of trial and comparative study 
designs. One patient representative expressed that the lan-
guage used throughout the survey was not friendly enough 
for participants and there were some irrelevant questions for 
them. However, the rest of the patient partners completed the 
survey without complications or raising any other concerns. 
In addition, there was some missing data within the dataset 
possibly affecting the robustness of the analysis.
This study evaluated the priorities for the UK’s regula-
tory science agenda post-Brexit and through the lens of the 
UK’s continuing response to COVID-19, particularly in the 
context of global opportunities. The authors find that trust, 
collaboration, leadership and training are vital for the UK’s 
current and future international position, both as a competi-
tive marketplace for innovation but also in supporting the 
voice of patients and the public as the UK accelerates safe 
and effective advances in healthcare; particular attention 
should be given to novel and innovative developments. This 
is a unique, challenging time for the UK—with reason to be 
optimistic if it can meet the challenges and opportunities 
outlined here with an open mind, clear strategy and com-
mitment to partnership.
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